Dr. Reddy’s appoints Marc Kikuchi as new head of generics business in North America

Dr. Reddy’s Laboratories has appointed Marc Kikuchi as CEO of its North America Generics unit.

As part of the senior leadership team of Dr. Reddy’s Laboratories, Marc Kikuchi will undertake responsibility of the pharma company’s North America Generics business and will work in Princeton office, US.

Marc Kikuchi said: “Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage.

“I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the Company’s new growth areas.”

Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. Photo: courtesy of Business Wire

Marc Kikuchi has more than 20 years of experience in the pharmaceutical industry. He is said to have vast knowledge and understanding of generics. He joins Dr. Reddy’s Laboratories from Zydus Pharmaceuticals, where he worked as CEO, Americas since 2016.

Before joining Zydus Pharmaceuticals, he had worked in AmerisourceBergen, Medrad, PRTM, Johnson & Johnson and also Incyte Pharmaceuticals.

Marc Kikuchi has a Bachelor’s Degree in Molecular and Cell Biology with a Biochemistry emphasis from the University of California at Berkeley in addition to Master of Business Administration from Carnegie Mellon University in Strategy, Marketing, and Operations Management.

Related posts

• FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint (0)
• GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group (0)
• Gemini Therapeutics appoints Jason Meyenburg as CEO (0)
• Castle Creek to acquire cell and gene therapy company Fibrocell (0)
• Eisai, Biogen to scrap elenbecestat phase 3 studies in early AD (0)
• Aytu BioScience to acquire Innovus Pharmaceuticals (0)
• Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m (0)
• Xeris Pharmaceuticals bags GVOKE FDA approval for severe hypoglycemia (0)
• ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients (0)
• Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD (0)